Intellectual Property and Technology Transfer Bruce Goldstein In: JI Gallin, FP Ognibene, LL Johnson, eds. Principles and Practice of Clinical Research (Fourth Edition). (Academic Press/Elsevier Inc.) 2017:447–529. |
|
A Guide to Time Lag and Time Lag Shortening Strategies in Oncology-Based Drug Development Berna Uygur, Josh Duberman, and Steven M. Ferguson J Commer Biotechnol. 2017 May;23(2):75-81. |
|
Beyond Hybrid Licenses—Strategies for Post Patent Expiration Payments in the United States Patrick Gattari, Steven Ferguson, David Crichton, and Bryan Helwig les Nouvelles. 2017 Mar;52(1):31-6. |
|
Licensing the Technology: Biotechnology Commercialization Strategies Using University and Federal Labs (2nd Edition) Steven M. Ferguson and Uma S. Kaundinya In: Craig Shimasaki, ed. Biotechnology Entrepreneurship: Starting, Managing, and Leading Biotech Companies. (Elsevier Inc.) 2020:199-222. |
|
NIH Inventions Translate into Drugs and Biologics with High Public Health Impact Sabarni K. Chatterjee and Mark L. Rohrbaugh Nat Biotechnol. 2014 Jan 9;32(1):52-8. |
|
If The Sky Were The Limit, What Would You Do In Technology Transfer? Gary Keller, Fizie Haleem, Steven Ferguson, Al Jordan, and Cheryl Cejka les Nouvelles. 2013 Mar;47(1):66-70. |
|
Partnering with the NIH: Now part of the "Value Proposition" for start-ups Steven M. Ferguson J Commer Biotechnol. 2012 Apr 1;18(2):60-67. |
|
License Compliance Issues for Biopharmaceuticals: Special Challenges for Negotiations between Companies and Non-Profit Research Institutions Todd A. Ponzio, Hans Feindt, and Steven M. Ferguson les Nouvelles, 2011 Sep;46(3):216-25. |
|
The Role of Public-Sector Research in the Discovery of Drugs and Vaccines Ashley J. Stevens, Jonathan J. Jensen, Katrine Wyller, Patrick C. Kilgore, Sabarni Chatterjee, and Mark L. Rohrbaugh N Engl J Med. 2011 Feb 10;364(6):535-41. |
|